Insilico Medicine and Taiwan-based Bora Pharmaceuticals announced a strategic alliance that extends generative AI beyond drug discovery into pharmaceutical manufacturing, with a potential value exceeding $2.5B.
The deal puts Insilico’s Pharma.AI platform — specifically its target-identification engine PandaOmics and molecular-design engine Chemistry42 — to work on manufacturing challenges: process optimization, batch quality control, and supply-chain coordination. It is the first large-scale attempt to apply drug-discovery-grade AI to the factory floor.
“AI is already transforming drug discovery, but its full potential will only be realized when that transformation extends across the entire development and manufacturing value chain,” said Bobby Sheng, founder and chairman of Bora Pharmaceuticals.
The global CDMO market is estimated at $168B and projected to reach $315B by 2034. If the Insilico-Bora alliance succeeds in demonstrating that AI can reduce batch failure rates and accelerate manufacturing readiness, AI competency could become a new axis of competitive differentiation in an industry that has historically competed on scale and compliance alone.
Insilico’s pipeline has produced 31 preclinical candidates since 2021, 13 of which have achieved IND approval or clearance. The company’s lead drug, rentosertib — where both the target and molecule were designed by AI — recently entered Phase III trials in China.
